World’s First Clinical Case of Gene-Activated Bone Substitute Application
Treatment of patients with large bone defects is a complex clinical problem. We have initiated the first clinical study of a gene-activated bone substitute composed of the collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor. The first patient with two nonunio...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | Case Reports in Dentistry |
Online Access: | http://dx.doi.org/10.1155/2016/8648949 |